Instil Bio Ends Development of Cancer Drug AXN-2510
Instil Bio's subsidiary Axion Bio discontinues clinical development of AXN-2510 and terminates collaboration agreement with ImmuneOnco, returning rights to the Chinese partner.
/ 907 items
#Healthcare↓
Cyclerion Partners with Medsteer to Advance Depression Treatment
Cyclerion Therapeutics teams up with Medsteer to develop CYC-126, an innovative therapy for treatment-resistant depression, with Phase 2 trials starting in 2026.
Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
Gyre Therapeutics Gains on China Drug Approval Pathway
Gyre Therapeutics (GYRE) stock jumps 14% after Chinese regulators agree to conditional approval pathway for Hydronidone, a first-in-class liver fibrosis treatment.
Altimmune Stock Surges on FDA Breakthrough Designation for Liver Disease Treatment
Altimmune shares jump 24% after FDA grants breakthrough therapy designation for pemvidutide, a promising treatment for MASH liver disease showing significant trial results.
Zenas BioPharma Crashes 53% Despite Meeting Trial Goals—Why Investors Aren't Buying It
Zenas BioPharma stock plunges over 50% after Phase 3 obexelimab trial results disappoint Wall Street, despite meeting all endpoints in rare autoimmune disease study.